Valneva SE (VALN) stock
VALNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$5.66−0.10 (-1.74%)
Close on Nov 13, 2026Market cap $491.12MP/E –Yield –
Valneva gross margin
Gross margin is gross profit as a percentage of revenue.
Valneva's gross margin for the twelve months ending Jun 30, 2026 was 16.4%. For fiscal 2025 it was 38.7%, against 41.9% the year before. The highest annual figure on record is 58.2% in fiscal 2019.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 38.7% | −3.2 |
| FY2024 | Dec 31, 2024 | 41.9% | +7.5 |
| FY2023 | Dec 31, 2023 | 34.4% | +24.2 |
| FY2022 | Dec 31, 2022 | 10.2% | −35.8 |
| FY2021 | Dec 31, 2021 | 46.0% | −4.8 |
| FY2020 | Dec 31, 2020 | 50.8% | −7.4 |
| FY2019 | Dec 31, 2019 | 58.2% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 4.6% | −45.5 |
| Q1 FY2026 | Mar 31, 2026 | 15.3% | −37.9 |
| Q4 FY2025 | Dec 31, 2025 | 24.4% | −24.2 |
| Q3 FY2025 | Sep 30, 2025 | 18.7% | −25.3 |
| Q2 FY2025 | Jun 30, 2025 | 50.1% | +11.8 |
| Q1 FY2025 | Mar 31, 2025 | 53.2% | +20.9 |
| Q4 FY2024 | Dec 31, 2024 | 48.6% | +10.8 |
| Q3 FY2024 | Sep 30, 2024 | 44.0% | −0.9 |
| Q2 FY2024 | Jun 30, 2024 | 38.3% | +21.2 |
| Q1 FY2024 | Mar 31, 2024 | 32.3% | −6.5 |
| Q4 FY2023 | Dec 31, 2023 | 37.8% | +47.0 |
| Q3 FY2023 | Sep 30, 2023 | 44.9% | −35.1 |
| Q2 FY2023 | Jun 30, 2023 | 17.1% | +137.9 |
| Q1 FY2023 | Mar 31, 2023 | 38.9% | +2.3 |
| Q4 FY2022 | Dec 31, 2022 | -9.3% | −99.1 |
| Q3 FY2022 | Sep 30, 2022 | 80.1% | +538.6 |
| Q2 FY2022 | Jun 30, 2022 | -120.8% | −138.0 |
| Q1 FY2022 | Mar 31, 2022 | 36.6% | −0.3 |
| Q4 FY2021 | Dec 31, 2021 | 89.8% | – |
| Q3 FY2021 | Sep 30, 2021 | -458.6% | – |
| Q2 FY2021 | Jun 30, 2021 | 17.1% | – |
| Q1 FY2021 | Mar 31, 2021 | 36.9% | – |
See a number that looks wrong?